Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics (NASDAQ:NMRA) and maintained a price target of $23.
October 18, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics and maintained a price target of $23, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst suggests a positive outlook for Neumora Therapeutics. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100